Skip to Content

Abiraterone Dosage

Applies to the following strength(s): 250 mg

The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Usual Adult Dose for:

Additional dosage information:

Usual Adult Dose for Prostate Cancer

1,000 mg orally once a day on an empty stomach (in combination with prednisone 5 mg orally 2 times a day)

Comments: No food should be consumed for at least 2 hours before the dose and for at least 1 hour after the dose of this drug.

Use: Treatment of metastatic castration-resistant prostate cancer

Renal Dose Adjustments

No adjustment recommended

Liver Dose Adjustments

-Mild Liver Dysfunction (Child-Pugh A): No adjustment recommended.
-Moderate Liver Dysfunction (Child-Pugh B): 250 mg orally once a day.
-Severe Liver Dysfunction (Child-Pugh C): Do not use.

Development of Hepatotoxicity (ALT and/or AST greater than 5 x ULN or total bilirubin greater than 3 x ULN) During Treatment:
-Interrupt treatment, then restart at a reduced dose of 750 mg orally once a day following return of liver function tests to the patient's baseline or to ALT and AST 2.5 x ULN or less and total bilirubin 1.5 x ULN or less.
-If hepatotoxicity recurs at 750 mg/day, then restart at a reduced dose of 500 mg orally once a day following return of liver function tests to the patient's baseline or to ALT and AST 2.5 x ULN or less and total bilirubin 1.5 x ULN or less.
-Discontinue treatment if hepatotoxicity recurs at 500 mg/day.

Development of Severe Hepatotoxicity (ALT or AST 20 x ULN) During Treatment:
-Permanently discontinue treatment.

Dose Adjustments

Concomitant Use of Strong CYP450 3A4 Inducer:
-Avoid concomitant use if possible.
-If concomitant use is necessary, increase the dosing frequency of this drug to 2 times a day during the co-administration period.
-Return to the previous dosing frequency once the strong CYP450 3A4 inducer is discontinued.

Concomitant Use of CYP450 2D6 Substrates with Narrow Therapeutic Index:
-Avoid concomitant use if possible.
-If concomitant use is necessary, consider a dose reduction of the CYP450 2D6 substrate during the co-administration period.

Precautions

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration Advice:
-This drug should be swallowed whole with water.
-Drug tablets should not be crushed or chewed.
-Pregnant women should not handle this drug without protection (e.g., gloves).
-In the event of a missed dose, the missed dose should be skipped and treatment should be resumed the following day with the usual daily dose.

General:
-Patients already receiving a gonadotropin-releasing hormone (GnRH) agonist should continue to take that drug during abiraterone treatment.

Monitoring:
-Cardiovascular: Cardiac function
-Endocrine: Blood pressure, serum potassium, fluid retention, signs/symptoms of adrenocortical insufficiency
-Hepatic: ALT, AST, bilirubin
-Metabolic: Blood sugar (in diabetic patients)

Hide